Dec 24 (Reuters) - Shares of Agios Pharmaceuticals (AGIO) jumped 18% on Wednesday after the U.S. Food and Drug Administration approved the expanded use of its drug for the treatment of a type of blood disorder.
The drug mitapivat is now approved as a treatment for patients with anemia in both non-transfusion-dependent and transfusion-dependent alpha- or beta-thalassemia, the company said late on Tuesday.
Thalassemia is an inherited blood disorder affecting the body's ability to produce hemoglobin and healthy red blood cells.
The drug, under the brand name Aqvesme, is expected to be available in late January next year, following the implementation of the required safety program.
Mitapivat was already approved by the U.S. FDA in 2022 to treat low red blood cell counts in adults with pyruvate kinase deficiency, under the brand name of Pyrukynd.
"The approval unlocks an additional $320 million in peak revenue opportunity layered atop the existing mitapivat franchise," Truist analyst Gregory Renza said.
The latest approval is based on a late-stage study in which patients receiving mitapivat showed a statistically significant increase in hemoglobin response compared to those on placebo.
Aqvesme will carry a boxed warning for liver function tests every four weeks during the first 24 weeks of treatment and advises against use in patients with cirrhosis, Renza added.
(Reporting by Siddhi Mahatole in Bengaluru; Editing by Vijay Kishore)
LATEST POSTS
- 1
Kenmore East reacts to their best overall delegation award at WNY Model United Nations General Assembly competition - 2Old age isn’t a modern phenomenon – many people lived long enough to grow old in the olden days, too
- 3VPN Administrations for Online Protection
- 4Must-See Attractions in Washington, D.C.
- 5Must-Sit in front of the Programs from Europe and the US
- The Best Cell phone Brands for Tech Lovers
- Brexit's Effect on New York's Ascent as a Main Monetary Center
- Motivational Travel Objections for History Buffs
- 6 Tire Brands Reasonable for Seniors
- Understanding climate change in America: Skepticism, dogmatism and personal experience
- Step by step instructions to Integrate Lab Precious stones into Special Adornments Pieces
- NASA unveils close-up pictures of the comet popping by from another star
- Watch SpaceX launch 119 payloads to orbit from California early on March 30
- The most effective method to Boost Benefits in Gold Speculation: Master Techniques and Tips
